Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6585-6590

  Chiu, Joanne ^a   Tang, Vikki ^a   Leung, Roland ^a   Wong, Hilda ^a   Chu, Kin Wah ^a   Poon, Jensen ^b   Epstein, Richard J ^c   Yau, Thomas ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Capecitabine; Colorectal cancer; XELOX

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; COLORECTAL NEOPLASMS; FEMALE; FOLLOW UP; HONG KONG; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TIME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HONG KONG; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 84922295558     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6585     Document Type: Article

References (18)

1. Andre T, Boni C, Navarro M, et al (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 27, 3109-16.
2. Celik I, Kars A, Guc D, Tekuzman G, Ruacan S (2002). Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest, 20, 333-9.
3. de Gramont A, de Gramont A, Chibaudel B, et al (2011). The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer, 10, 218-26
4. Haller DG, Cassidy J, Clarke SJ, et al (2008). Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol, 26, 2118-23.
5. Haller DG, Tabernero J, Maroun J, et al (2011). Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol, 29, 1465-71.
6. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al (2001). Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 345, 638-46.
7. Law CC, Fu YT, Chau KK, et al (2007). Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. Dis Colon Rectum, 50, 2180-7.
8. McCall JL, Cox MR, Wattchow DA (1995). Analysis of local recurrence rates after surgery alone for rectal cancer. Int J Colorectal Dis, 10, 126-32.
9. McCollum AD, Catalano PJ, Haller DG, et al (2002). Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst, 94, 1160-7.
10. O'Connell MJ, Martenson JA, Wieand HS, et al (1994). Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med, 331, 502-7.
11. Raida M, Schwabe W, Hausler P, et al (2001). Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res, 7, 2832-9.
12. Reddy GK (2004). Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: results from the X-ACT trial. Clin Colorectal Cancer, 4, 87-8.
13. Sargent DJ, Patiyil S, Yothers G, et al (2007). End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol, 25, 4569-74.
14. Schmoll HJ, Cartwright T, Tabernero J, et al (2007). Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol, 25, 102-9.
15. Teitelbaum UR, Haller DG (2009). Medical Oncology: Secondline XELOX or FOLFOX-4 for metastatic colorectal cancer. Nat Rev Clin Oncol, 6, 250-1.
16. Tse VC, Ng WT, Lee V, et al (2011). Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. BMC Cancer, 11, 288.
17. Wei X, Elizondo G, Sapone A, et al (1998). Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics, 51, 391-400.
18. Yothers G, O'Connell MJ, Allegra CJ, et al (2011). Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol, 29, 3768-74.